CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Encouraging results from early-stage trials of its experimental anti-HIV drug SP01A have led drugmaker Samaritan Pharmaceuticals to accelerate plans for a Phase III trial, the Associated Press reports. The final-stage human trial will begin soon in Europe, even as a Phase II trial of the drug remains under way. The Phase III trial will include 411 patients who will take the drug for 48 weeks, company officials say. SP01A is an experimental entry inhibitor that aims to prevent HIV from entering immune system cells. Studies have shown it is effective in controlling HIV that is resistant to other anti-HIV medications. (The Advocate)
From our Sponsors
Most Popular
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Latest Stories
Emanuele Crialese on His Autobiographical Coming-of-age Trans Film, L'immensitÃ
January 19 2023 8:02 PM
CPAC's Matt Schlapp & Wife Sued By GOP Staffer For Sex Harassment, Defamation
January 19 2023 5:13 PM
'Elm Street' Star Mark Patton Hospitalized With AIDS Complications, Seeks Help
January 19 2023 9:12 AM
Advocate Channel
Health